Cytokinetics to Announce Second Quarter Results on August 8, 2024
Cytokinetics (Nasdaq: CYTK) has announced that it will release its second quarter 2024 financial results on August 8, 2024, at 4:00 PM Eastern Time. Following the announcement, the company's senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results, as well as the company's future outlook.
Investors and interested parties can access the conference call through a simultaneous webcast available on the Investors & Media section of Cytokinetics' website. Additionally, participants can join the call via telephone by registering in advance through a provided link. An archived replay of the webcast will be accessible on the company's website for twelve months after the event.
Cytokinetics (Nasdaq: CYTK) ha annunciato che rilascerà i suoi risultati finanziari per il secondo trimestre del 2024 il 8 agosto 2024, alle 16:00 ora orientale. Dopo l'annuncio, il senior management dell'azienda ospiterà una conf-call alle 16:30 ora orientale per discutere i risultati operativi e finanziari, oltre alle prospettive future dell'azienda.
Gli investitori e gli interessati possono accedere alla conf-call tramite un webcast simultaneo disponibile nella sezione Investitori e Media del sito web di Cytokinetics. Inoltre, i partecipanti possono unirsi alla chiamata via telefono registrandosi in anticipo tramite un link fornito. Una registrazione dell'archivio del webcast sarà accessibile sul sito dell'azienda per dodici mesi dopo l'evento.
Cytokinetics (Nasdaq: CYTK) ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el 8 de agosto de 2024, a las 4:00 PM hora del Este. Después del anuncio, la alta dirección de la empresa llevará a cabo una llamada de conferencia a las 4:30 PM hora del Este para discutir los resultados operativos y financieros, así como las perspectivas futuras de la empresa.
Los inversores y partes interesadas pueden acceder a la llamada de conferencia a través de un webcast simultáneo disponible en la sección de Inversores y Medios del sitio web de Cytokinetics. Además, los participantes pueden unirse a la llamada por teléfono registrándose con anticipación a través de un enlace proporcionado. Una retransmisión archivada del webcast estará disponible en el sitio web de la empresa durante doce meses después del evento.
Cytokinetics (Nasdaq: CYTK)는 2024년 2분기 재무 결과를 2024년 8월 8일 동부 시간 오후 4:00에 발표할 것이라고 발표했습니다. 발표 이후, 회사의 고위 경영진은 동부 시간 오후 4:30에 운영 및 재무 결과, 그리고 회사의 미래 전망에 대해 논의하는 컨퍼런스 콜를 주최합니다.
투자자와 관심 있는 당사자는 Cytokinetics 웹사이트의 투자자 및 미디어 섹션에서 제공되는 동시 웹캐스트를 통해 컨퍼런스 콜에 접근할 수 있습니다. 또한, 참가자는 제공된 링크를 통해 사전 등록하여 전화로 콜에 참여할 수 있습니다. 웹캐스트의 아카이브 재생은 이벤트 종료 후 12개월 동안 회사의 웹사이트에서 열람 가능합니다.
Cytokinetics (Nasdaq: CYTK) a annoncé qu'elle publiera ses résultats financiers pour le deuxième trimestre 2024 le 8 août 2024 à 16h00 heure de l'Est. Suite à cette annonce, la direction de l'entreprise organisera une conférence téléphonique à 16h30 heure de l'Est pour discuter des résultats opérationnels et financiers, ainsi que des perspectives futures de l'entreprise.
Les investisseurs et les parties intéressées peuvent accéder à la conférence téléphonique via un webinaire simultané disponible dans la section Investisseurs et Médias du site web de Cytokinetics. De plus, les participants peuvent rejoindre l'appel par téléphone en se registrant à l'avance via un lien fourni. Un rediffusion archivée du webinaire sera accessible sur le site de l'entreprise pendant douze mois après l'événement.
Cytokinetics (Nasdaq: CYTK) hat angekündigt, dass es am 8. August 2024 um 16:00 Uhr Eastern Time seine Finanzergebnisse für das zweite Quartal 2024 veröffentlichen wird. Nach der Ankündigung wird das obere Management des Unternehmens um 16:30 Uhr Eastern Time eine Telefonkonferenz abhalten, um die operativen und finanziellen Ergebnisse sowie die zukünftigen Aussichten des Unternehmens zu besprechen.
Investoren und interessierte Parteien können über ein simultanes Webcast auf den Investoren- und Medienbereich der Cytokinetics-Website auf die Telefonkonferenz zugreifen. Darüber hinaus können die Teilnehmer durch vorausgehende Registrierung über einen bereitgestellten Link telefonisch an der Konferenz teilnehmen. Eine archivierte Wiedergabe des Webcasts wird auf der Unternehmenswebsite für zwölf Monate nach der Veranstaltung verfügbar sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 8, 2024 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future.
The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by registering in advance at the following link: Cytokinetics Q2 2024 Earnings Conference Call. Upon registration, participants will receive a dial-in number and a unique passcode to access the call. An archived replay of the webcast will be available via Cytokinetics’ website for twelve months.
About Cytokinetics
Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF, and CK-136, a cardiac troponin activator for the potential treatment HFrEF and other types of heart failure, such as right ventricular failure resulting from impaired cardiac contractility.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
FAQ
When will Cytokinetics (CYTK) report its Q2 2024 financial results?
How can investors access Cytokinetics' (CYTK) Q2 2024 earnings conference call?
What time is Cytokinetics' (CYTK) Q2 2024 earnings conference call scheduled?
How long will the replay of Cytokinetics' (CYTK) Q2 2024 earnings call be available?
